1. Vockley J. Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care. 2020;26(7):S147-S154.
  2. Merritt JL 2nd, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020;21(4):479-493.
  3. Vockley J, Burton B, Berry G, et al. Effects of triheptanoin (UX007) in patients with long-chain fatty acid disorders: results from an open label, long-term extension study. J Inherit Metab Dis. 2020;44(1):253-263.
  4. Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93-106.
  5. Steptoe A, Mohabir A, Mahon NG, McKenna WJ. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart. 2000;83(6):645-650.
  6. Siddiq S, Wilson BJ, Graham ID; Canadian Inherited Metabolic Diseases Research Network (CIMDRN). Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis. 2016;11(1):168.
  7. Baumbusch J, Mayer S, Sloan-Yip I. Alone in a crowd? Parents of children with rare diseases’ experiences of navigating the healthcare system. J Genet Couns. 2018;1:80-90.
  8. Southeast Regional Genetics Network, Genetic Metabolic Dietitians International. VLCAD nutrition management guidelines. February 2019, v 1.0. 1st ed. Accessed May 12, 2021.
  9. Spiekerkoetter U, Lindner M, Santer R, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32(4):498-505.
  10. Angelini C, Federico A, Reichmann H, Lombes A, Chinnery P, Turnbull D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol. 2006;13(9):923-929.
  11. International Network for Fatty Acid Oxidation Research and Management. FAOD diagnosis. Accessed May 12, 2021.
  12. Van Calcar SC, Sowa M, Rohr F, et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach. Mol Genet Metab. 2020;131(1-2):23-37.
  13. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. The National Academies Press, 2005.
  14. Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473.
  15. Shirley M. Triheptanoin: first approval. Drugs. 2020;80(15):1595-1600.
  16. Dojolvi prescribing information. Ultragenyx Pharmaceutical Inc.; 2020.
  17. Ultragenyx Pharmaceutical Inc press release. Ultragenyx announces approval of Dojolvi™ (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children. February 17, 2021.
  18. Vockley J, Burton B, Berry GT, et al. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis. 2019;42(1):169-177.
  19. Gillingham MB, Heitner SB, Martin J, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40(6):831-843.
  20. Vockley J, Longo N, Madden M, et al. Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study. Clin Nutr ESPEN. 2021;41:293-298.
  21. Zand D, Doan J, Yi S, et al. Regulatory news: Dojolvi (triheptanoin) as a source of calories and fatty acids in long-chain fatty acid oxidation disorders: FDA approval summary. J Inherit Metab Dis. 2021;44(3):515-517.
  22. Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23(5):816-829.
  23. Potter BK, Chakraborty P, Kronick JB, et al; Canadian Inherited Metabolic Diseases Research Network. Achieving the “triple aim” for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genet Med. 2013;15(6):415-422.
  24. McClain MR, Cooley WC, Keirns T, Smith A. A survey of the preferences of primary care physicians regarding the comanagement with specialists of children with rare or complex conditions. Clin Pediatr (Phila). 2014;53(6):566-570.